Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research16

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research16

FiltersClear all

Status

Recruiting7
Active, not recruiting2
Completed7

Study type

Interventional16

Phase

Phase 312
Phase 22
Not applicable2

Investigator

Alpana P. Shukla7
Louis J Aronne5
Ana C. Krieger2
Daniel W Skupski1
Reem Z. Sharaiha1

Department

Medicine15
Obstetrics and Gynecology1

Condition

Overweight15
Prostatic Neoplasms52
Leukemia, Myeloid, Acute50
Breast Neoplasms43
Heart Failure34

Show all 50

Intervention type

Drug14
Other4
Behavioral1
Biological1
Device1

Sponsor type

Industry15
Other academic1

Start date

Has results posted5

Overweight×Clear all

Showing 1–16 of 16 studiesSort:

Active, not recruitingInterventional · Phase 3NCT05869903 ↗
A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)
Alpana P. ShuklaPI
Intervention
Drug: Orforglipron · Drug: Placebo
Dates
Jun 2023 – Jul 2025

FiltersClear all

Status

Recruiting7
Active, not recruiting2
Completed7

Study type

Interventional16

Phase

Phase 312
Phase 22
Not applicable2

Investigator

Alpana P. Shukla7
Louis J Aronne5
Ana C. Krieger2
Daniel W Skupski1
Reem Z. Sharaiha1

Department

Medicine15
Obstetrics and Gynecology1

Condition

Overweight15
Prostatic Neoplasms52
Leukemia, Myeloid, Acute50
Breast Neoplasms43
Heart Failure34

Show all 50

Intervention type

Drug14
Other4
Behavioral1
Biological1
Device1

Sponsor type

Industry15
Other academic1

Start date

Has results posted5

Overweight×Clear all

Showing 1–16 of 16 studiesSort:

Active, not recruitingInterventional · Phase 3NCT05869903 ↗
A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)
Alpana P. ShuklaPI
Intervention
Drug: Orforglipron · Drug: Placebo
Dates
Jun 2023 – Jul 2025

Show fewer

Multiple Myeloma32
Neoplasms32
Colitis, Ulcerative29
Atrial Fibrillation27
Carcinoma, Non-Small-Cell Lung27
Crohn Disease27
Recurrence27
COVID-1926
Myelodysplastic Syndromes26
Parkinson Disease24
Neoplasm Metastasis23
Obesity23
Colorectal Neoplasms19
HIV Infections19
Hematologic Neoplasms19
Cardiovascular Diseases18
Depression18
Non-alcoholic Fatty Liver Disease16
Lung Neoplasms14
Melanoma14
Cognitive Dysfunction13
Idiopathic Pulmonary Fibrosis13
Inflammatory Bowel Diseases13
Alzheimer Disease12
Leukemia12
Leukemia, Lymphocytic, Chronic, B-Cell12
Lymphoma, Non-Hodgkin12
Primary Myelofibrosis12
Coronary Artery Disease11
Hypertension11
Hypertension, Pulmonary11
Lung Diseases, Interstitial11
Myeloproliferative Disorders11
Pulmonary Arterial Hypertension11
Stroke11
Chronic Pain10
Hemophilia A10
Leukemia, Myelomonocytic, Chronic10
Lymphoma, Follicular10
Lymphoma, Large B-Cell, Diffuse10
Urinary Bladder Neoplasms10
Burkitt Lymphoma9
Fibrosis9
Liver Diseases9
Carcinoma, Renal Cell8

· Results posted

Sponsor

Eli Lilly and Company

ObesityOverweightOverweight or Obesity

RecruitingInterventional · Not applicableNCT06724172 ↗

CHIME: Comparing Health Interventions for Maternal Equity

Daniel W SkupskiPI

Intervention: Behavioral: Self-Management · Behavioral: Community-Based
Dates: Jan 2026 – Jan 2030 (est.)
Sponsor: Stanford University

Obesity and OverweightNutritionChronic Disease+2 more

RecruitingInterventional · Not applicableNCT07090005 ↗

Comparing the Efficacy and Safety of the EndoZipTM System and Apollo Endoscopic Sleeve Gastroplasty (ESG), Followed by Behavioral Modifications, in Obese Patients Who Have Not Achieved Weight Reduction Through Non-surgical Methods.

Reem Z. SharaihaPI

Intervention: Device: EndoZip System · Device: OverStitch Endoscopic Suturing System (ESG)
Dates: Nov 2025 – Jun 2027 (est.)
Sponsor: Nitinotes Surgical Ltd.

ObesityOverweight

Active, not recruitingInterventional · Phase 3NCT07357415 ↗

A Phase 3b Study to Investigate the Efficacy and Safety of Different Retatrutide Dose Escalation Schemes in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Controlled, Double-Blind Trial

Alpana P. ShuklaPI

Intervention: Drug: Retatrutide
Dates: Jan 2026 – Oct 2028 (est.)
Sponsor: Eli Lilly and Company

ObesityOverweight

RecruitingInterventional · Phase 3NCT07392190 ↗

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes

Louis J AronnePI

Intervention: Drug: Eloralintide · Drug: Placebo
Dates: Feb 2026 – Jun 2028 (est.)
Sponsor: Eli Lilly and Company

OverweightObesity

RecruitingInterventional · Phase 3NCT07571005 ↗

Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure (AMAZE 3)

Ana C. KriegerPI

Intervention: Drug: NNC0487-0111 · Drug: Placebo (matched to NNC0487-0111)
Dates: May 2026 – Jul 2028 (est.)
Sponsor: Novo Nordisk Pharmaceuticals, Inc.

ObesityOverweightObstructive Sleep Apnoea

RecruitingInterventional · Phase 3NCT07571109 ↗

Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Obstructive Sleep Apnoea Treated With Positive Airway Pressure (AMAZE 4)

Ana C. KriegerPI

Intervention: Drug: NNC0487-0111 · Drug: Placebo (matched to NNC0487-0111)
Dates: May 2026 – Jun 2028 (est.)
Sponsor: Novo Nordisk Pharmaceuticals, Inc.

ObesityOverweightObstructive Sleep Apnoea

RecruitingInterventional · Phase 3NCT07595549 ↗

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY PF-08653944 IN ADULTS WITH OVERWEIGHT OR OBESITY (VESPER-6)

Alpana P. ShuklaPI

Intervention: Drug: PF-08653944 · Other: Placebo
Dates: Jun 2026 – May 2028 (est.)
Sponsor: Pfizer, Inc.

ObesityOverweight and/or ObesityOverweight

RecruitingInterventional · Phase 3NCT07720271 ↗

Efficacy and Safety of Once-daily Oral Zenagamtide in Participants With Obesity (AMAZE 9)

Alpana P. ShuklaPI

Intervention: Drug: zenagamtide · Drug: Placebo
Dates: Aug 2026 – Jun 2028 (est.)
Sponsor: Novo Nordisk Pharmaceuticals, Inc.

OverweightObesity

CompletedInterventional · Phase 3NCT04184622 ↗

Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)

Louis J AronnePI

Intervention: Drug: Tirzepatide · Drug: Placebo
Dates: Dec 2019 – Apr 2022· Results posted
Sponsor: Lilly USA, LLC

OverweightObesity

CompletedInterventional · Phase 3NCT04660643 ↗

Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)

Louis J AronnePI

Intervention: Drug: Tirzepatide · Other: Placebo
Dates: Mar 2021 – Apr 2023· Results posted
Sponsor: Eli Lilly and Company

ObesityOverweight

CompletedInterventional · Phase 2NCT05295875 ↗

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled and Parallel Group 48-Week Study to Evaluate the Efficacy and Safety of ALT-801 in the Treatment of Obesity (MOMENTUM Trial)

Louis J AronnePI

Intervention: Drug: ALT-801 · Other: Placebo
Dates: Mar 2022 – Sep 2023
Sponsor: Altimmune, Inc.

Obesity/Overweight

CompletedInterventional · Phase 3NCT05394519 ↗

Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity and Type 2 Diabetes

Alpana P. ShuklaPI

Intervention: Drug: Cagrilintide · Drug: Semaglutide · Drug: Placebo cagrilintide · Drug: Placebo semaglutide
Dates: Feb 2023 – Jan 2025
Sponsor: Novo Nordisk Pharmaceuticals, Inc.

OverweightObesityType 2 Diabetes Mellitus

CompletedInterventional · Phase 2NCT05616013 ↗

A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Intravenous Bimagrumab, Alone or in Addition to Open Label Subcutaneous Semaglutide, to Investigate the Efficacy and Safety in Overweight or Obese Men and Women

Louis J AronnePI

Intervention: Biological: Bimagrumab · Drug: Semaglutide · Other: Placebo
Dates: Nov 2022 – May 2024· Results posted
Sponsor: Versanis Bio

ObesityObeseOverweight or Obesity

CompletedInterventional · Phase 3NCT05822830 ↗

A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide in Adults Who Have Obesity or Overweight With Weight Related Comorbidities

Alpana P. ShuklaPI

Intervention: Drug: Tirzepatide · Drug: Semaglutide
Dates: Apr 2023 – Nov 2024· Results posted
Sponsor: Eli Lilly and Company

ObesityOverweight

CompletedInterventional · Phase 3NCT06584916 ↗

A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Orforglipron Once Daily Versus Placebo for Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Alpana P. ShuklaPI

Intervention: Drug: Orforglipron · Drug: Placebo
Dates: Sep 2024 – Nov 2025
Sponsor: Eli Lilly and Company

ObesityOverweight